CompletedNCT00589914
Paliperidone or long-acting risperidone for schizophrenia
About this title
Read the official source — NCT00589914Researchers compared Paliperidone palmitate and RISPERDAL CONSTA to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18+Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Paliperidone palmitate and RISPERDAL CONSTA to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 81 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,221
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Austria, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00589914
- Official title
Show the full official title
A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Little Rock, United States · Cerritos, United States
81 more locations
- Garden Grove, United States
- Los Angeles, United States
- Washington D.C., United States
- Atlanta, United States
- Chicago, United States
- Flowood, United States
- Hollis, United States
- Willoughby, United States
- Oklahoma City, United States
- DeSoto, United States
- Houston, United States
- Odessa, United States
- Linz, Austria
- Salzburg, Austria
- Vienna, Austria
- Plovdiv, Bulgaria
- Varna, Bulgaria
- Brno, Czechia
- Dobřany, Czechia
- Kroměříž, Czechia
- Kutná Hora, Czechia
- Olomouc, Czechia
- Prague, Czechia
- Pärnu, Estonia
- Tallinn, Estonia
- Tartu, Estonia
- Bourges Cedex N/A, France
- Dole, France
- Romans-sur-Isère, France
- Achim, Germany
- Berlin, Germany
- Bielefeld, Germany
- Bochum, Germany
- Jena, Germany
- Leipzig, Germany
- Mannheim, Germany
- München, Germany
- Stralsund, Germany
- Baja, Hungary
- Budapest, Hungary
- Gyõr, Hungary
- Kalocsa, Hungary
- Nagykálló, Hungary
- Bangalore, India
- Chandigarh, India
- Chhatrapati Sambhajinagar, India
- Mangalore, India
- Pune, India
- Varanasi, India
- Alytus, Lithuania
- Kaunas, Lithuania
- Klaipėda, Lithuania
- Vilnius, Lithuania
- Bełchatów, Poland
- Bytom Na, Poland
- Chełmno, Poland
- Gdynia Na, Poland
- Katowice Woj Slaskie, Poland
- Krakow Na, Poland
- Lubliniec, Poland
- Piekary Slaskie Na, Poland
- Skorzewo Na, Poland
- Warszawa Na, Poland
- Moscow, Russia
- Moscow Russia, Russia
- Nizny Novgorod, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Yaroslavl, Russia
- Barcelona, Spain
- Madrid, Spain
- San Juan, Spain
- Dnipro, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Kyiv, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Czechia
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Paliperidone palmitate and RISPERDAL CONSTA to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including RISPERDAL CONSTA and Paliperidone palmitate.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia